Real-world assessment of ipi-nivo in anti-PD-(L)-1 refractory Merkel Cell Carcinoma
2022
Real world evaluation of ipilimumab/nivolumab in PD-1/PDL-1 refractory MCC
Event
2nd International Symposium on Merkel Cell Carcinoma, University of Washington School of Medicine
This site represents our opinions only. See our full Disclaimer and Terms of Use Agreement